BS_VJVDJABP
Embryonal tumors
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Embryonal tumors
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Embryonal tumors
- overall_survival_months
- 36.16951379763469
- age_years
- 5.584
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.430
- MYC_TARGETS_V2+0.404
- OXIDATIVE_PHOSPHORYLATION+0.307
- UNFOLDED_PROTEIN_RESPONSE+0.300
- DNA_REPAIR+0.256
- PROTEIN_SECRETION+0.247
- PEROXISOME+0.159
- WNT_BETA_CATENIN_SIGNALING+0.157
- BILE_ACID_METABOLISM+0.096
- HEME_METABOLISM+0.088
Top 10 suppressed
- ANGIOGENESIS-0.565
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.551
- IL6_JAK_STAT3_SIGNALING-0.500
- ALLOGRAFT_REJECTION-0.482
- INFLAMMATORY_RESPONSE-0.469
- TNFA_SIGNALING_VIA_NFKB-0.449
- COAGULATION-0.437
- COMPLEMENT-0.400
- INTERFERON_GAMMA_RESPONSE-0.388
- HEDGEHOG_SIGNALING-0.334
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K74PZET7 | Med | Medulloblastoma | 0.913 |
| 2 | R16 | — | — | 0.895 |
| 3 | s0095168 | — | — | 0.891 |
| 4 | SRR5088889 | — | — | 0.889 |
| 5 | BS_SDCNP7MW | Ependymoma NOS | — | 0.878 |
| 6 | BS_VA5T4KAA | medulloblastoma | — | 0.877 |
| 7 | TCGA-AR-A0TR-01A-11R-A084-07 | — | B | 0.876 |
| 8 | DRR168565 | — | — | 0.876 |
| 9 | SRR1797243 | — | cohortSC | 0.874 |
| 10 | AUR-AFKB-TTM1-A-1-1-R-A742-41 | — | C | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.404 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.307 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.256 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.247 | Remibrutinib | — uncovered |
| PEROXISOME | 0.159 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.157 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.096 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.088 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.021 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.001 | Inavolisib | — uncovered |